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Extracellular fluid levels of the neurotoxin quinolinic acid in the corpus striatum of rats, measured by in vivo microdialy- 
sis, were increased in a dose-dependent manner following the intraperitoneal administration of tryptophan. The lowest 
dose of tryptophan (12.5 mg/kg), equivalent o about 5% of the normal daily intake, increased peak quinolinic acid levels 
nearly 3-fold. At higher doses of tryptophan (up to 250 mg/kg), concentrations of quinolinic acid increased over 200-fold 
and exceeded potentially neurotoxic levels (10 PM). In contrast, the increase in extracellular serotonin following even 
the highest ryptophan dose was small (less than 2-fold). These data indicate that quinolinic acid is present in the extracel- 
lular fluid where it may function as a neuromodulator and that it is very responsive to physiological changes in precursor 
availability. 
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1. INTRODUCTION 
The precursor relationship of the essential 
aromatic amino acid, L-tryptophan to the neuro- 
transmitter serotonin (5hydroxytryptamine, 5- 
HT) is well established [l-8]. Indeed, therapeutic 
interventions for several neuropsychiatric and 
other disorders are based on this relationship. 
These include mania and depression, insomnia, 
obesity, hypertension, pain and aggression [9-161. 
The rationale behind this therapy is the recognition 
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that after crossing the blood-brain barrier, tryp- 
tophan is hydroxylated by tryptophan 5-monoxy- 
genase, to 5hydroxytryptophan and then decar- 
boxylated to 5-HT. In the central nervous system 
(CNS), tryptophan 5-monoxygenase is restricted to 
serotoninergic neurons and hence oral administra- 
tion of tryptophan is believed to increase selectively 
5-HT synthesis and release from serotoninergic 
neurons. 
However, the metabolism of tryptophan is com- 
plex and 5-HT is neither the major nor the only 
neuroactive tryptophan metabolite. Following a 
systemic load, the amount of tryptophan available 
to the brain for 5-HT synthesis is estimated to be 
only 3% of that administered [ 19,201. In the 
periphery the vast majority of tryptophan not used 
for protein synthesis is metabolized in the liver 
through the kynurenine pathway via the hepatic en- 
zyme tryptophan 2,3-dioxygenase. Although this 
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enzyme is found exclusively in the liver, indole 
2,3-dioxygenase has been shown to be present in 
other tissues including the brain [21-231. However, 
both the activity and function of the kynurenine 
pathway in the brain are poorly characterized [24]. 
Of the several neuroactive intermediates of 
kynurenine metabolism, including kynurenine 
itself, perhaps the most relevant is quinolinic acid 
(QUIN). As an agonist of the N-methyl-D-aspar- 
tate (N-Me-D-Asp)-type excitatory amino acid 
receptor [25], this dicarboxylic acid is an excitotox- 
in [26-281, and has been implicated in the 
pathogenesis of a number of neurological and 
metabolic disorders, including Huntington’s 
Disease, temporal lobe epilepsy, hepatic encep- 
halopathy and glutaric aciduria [29-341. 
We were interested in determining whether a 
physiological coupling of substrate control, similar 
to the relationship observed between brain tryp- 
tophan availability and serotoninergic neurotrans- 
mission, also existed between tryptophan and 
QUIN. Specifically, we wished to demonstrate a 
metabolic relationship using systemic doses of 
tryptophan that are believed to elevate plasma and 
brain tryptophan concentrations to levels within 
the physiological range. The concentrations of 
tryptophan in both plasma and brain exhibit a diur- 
nal variation with nocturnal peak levels typically 50 
to 15OYo above the daytime nadir [35]. A tryp- 
tophan dose of 12.5 mg/kg intraperitoneally is less 
than 5% of the normal daily intake and increases 
plasma and brain tryptophan to levels which do not 
exceed their normal daily peaks [36]. A precursor 
relationship of QUIN in the CNS to systemic levels 
of tryptophan would have several major implica- 
tions: (i) The generation of a mechanism whereby 
plasma fluctuations in tryptophan may influence 
brain levels of a potent neurotoxin. (ii) QUIN 
might mediate some of the CNS effects attributed 
to alterations in brain tryptophan levels. (iii) At 
high doses systemic administration of tryptophan 
might elicit selective neuronal cell loss comparable 
to that found in Huntington’s Disease. 
The site of action of 5-HT, and potentially 
QUIN, is the synaptic cleft. This space is hidden 
from current neurochemical techniques. However, 
recent developments in in vivo perfusion, in par- 
ticular, microdialysis, have enabled sampling of 
brain extracellular fluid (ECF), a space believed to 
be in equilibrium with the synaptic fluid. Measure- 
ment using this technique reveals the spillover of 
released neurotransmitters and metabolites and 
provides a dynamic record of synaptic events 
averaged over several minutes [37]. We have used 
this technique to follow the extracellular concen- 
trations of tryptophan and some of its metabolites 
in the striatum following systemic tryptophan ad- 
ministration. 
We have chosen the corpus striatum for two 
reasons. First, the N-Me-D-Asp receptor, which is 
unevenly distributed in mammalian brain, is pre- 
sent in high concentrations in the striatum [38]. 
This may account for the regional variation in 
neurotoxic sensitivity observed with a low thresh- 
old for toxicity found in the corpus striatum [39]. 
Second, the neostriatum is also the brain region 
primarily affected in Huntington’s Disease. 
2. EXPERIMENTAL 
Male Sprague-Dawley rats (250-350 g) were housed in a 
animal facility with ad libitum access to Agway 3000 (Syracuse, 
NY) rat chow. On the morning (08 : OO-09 : 00 h) of the day of 
experimentation, rats were anesthetized with chloralose/ure- 
thane (SO/500 mg . kg-‘) intraperitoneally with small, additional 
doses administered as necessary to maintain stable levels of 
anesthesia. Rats were placed in a Kopf stereotaxic frame and 
kept at 37°C using a homeostatically controlled heating pad. 
Dialysis probes were implanted into left and right striata at 
coordinates AP: +O.S, L: 2.5, V: -7.0 [40]. Correct probe 
placement was verified by post-mortem sectioning and light 
microscope visualization. 
The probes were of cannula design and had a 4 mm length of 
exposed membrane; the diffusion surface spanned the entire 
dorsoventral coordinates of the striatum. Probes were con- 
structed using the design of Sandberg et al. [41] with minor 
modifications. Hollow dialysis fibers (5 kDa cut-off; Cupro- 
phan, Hospal, Edison, NJ) were sealed at one end with epoxy 
resin (Devcon, Danvers, MA). A length of hollow vitreous silica 
fiber (0.17 mm outer diameter, Anspec, Ml) was inserted into 
the dialysis tube flush to the sealed end. The dialysis tubing with 
the vitreous silica fiber in situ was then inserted through a length 
of 23 gauge stainless-steel tubing into which another length of 
vitreous silica fiber (the outlet) had been placed. Both ends of 
the 23 gauge tubing were sealed with epoxy resin, with the 
dialysis membrane protruding from one end of the probe. The 
length of exposed membrane surface was controlled by coating 
the dialysis membrane with epoxy resin. 23 gauge tubing was 
glued with epoxy to the inlet vitreous tube enabling the probe to 
be perfused using a Harvard microperfusion pump (Harvard In- 
struments, Natick, MA) via PE-50 tubing. The probes were per- 
fused with an artificial ECF (12.5 mM Na+, 2.8 mM Kf, 1.0 mM 
Mg’+, . 1 2 mM Ca’+, 100 PM ascorbate, 2 mM phosphate, pH 
7.4) at 0.6 &min. Probes were calibrated in vitro by placing 
them in standard solutions (1O-6 and lo-’ M) and determining 
the relative concentration recovered. 
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The left striatal dialysates were assayed for QUIN using 
negative ionization gas chromatography mass spectrometry as 
described [42,43] and the right dialysates were analyzed for tryp- 
tophan, 5-HT and its acidic metabolite, 5hydroxyindoleacetic 
acid (5HIAA) using HPLC with electrochemical detection. The 
HPLC system used a 15 cm by 2.1 mm 3 pm Cl8 narrow-bore 
column with a low-volume (< 0.1 ,ul) electrochemical cell with 
an applied voltage of 0.95 V using a BAS LC3 potentiostat 
(Bioanalytical Systems, West Lafayette, IN). The mobile phase 
used to achieve separation was 0.06 M sodium phosphate buf- 
fer, 0.2 mM EDTA, 0.5 mM heptanesulfonic acid and 25% 
methanol (v/v), pH 2.1. Dialysate samples were injected directly 
onto the HPLC column without any need for an internal stan- 
dard or sample preparation. Chromatograms were completed 
within 25 min. Detection limits with a signal-to-noise ratio ex- 
ceeding 2: 1 were 5 fmol for 5-HT and 5-H&4, and 200 fmol 
per sample for tryptophan. Additional characterization of the 
5-HT signal included a greater than 60% reduction in peak 
height following p-chlorophenylalanine (150 mg/kg slow in- 
travenous infusion) and verification by Dr G.M. Anderson of 
selected samples using HPLC with fluorometric detection (441. 
Groups of rats received saline, or tryptophan in doses of 12.5, 
50, and 100 mg/kg intraperitoneally. L-Tryptophan (Sigma, St. 
Louis, MO) was administered as a saline solution in a volume of 
5 ml/kg. The tryptophan was dissolved in 1 M NaOH, diluted 
close to final volume with 0.9% saline, then adjusted to pH 7.4 
using 6 M HCI, with saline added to final volume. Treatments 
were administered following three 30-min baseline samples, col- 
lected at approx. 120-210 min following probe implantation. 
Perfusion continued for 3 h after treatments, with dialysates 
taken at 30-min intervals. Samples for QUIN assay were im- 
mediately frozen on dry ice and stored at - 70°C until assay. 
The dialysates for tryptophan, 5-HIAA and 5-HT measure- 
ments were directly injected onto the HPLC system. 
As an additional control to ensure that dialysate QUIN 
represented e novo brain synthesis and ECF spillover, and not 
disruption of the blood-brain barrier, a group of rats were can- 
nulated with intrafemoral catheters prior to dialysis probe im- 
plantation. These rats underwent simultaneous dialysis and 
plasma measurements following the intravenous administration 
of QUIN (2.5 mmol/kg). Plasma QUIN levels increased by 
IOO-fold, whereas dialysate QUIN concentrations remained un- 
changed (not shown). 
3. RESULTS 
Dialysate tryptophan levels remained stable in 
the saline-treated animals but increased by 
4.7 + l.Cfold in the 50 mg/kg group and by 
6.5 +0.6-fold in the 100 mg/kg treated animals 
(fig.1). QUIN increased markedly by 2.9 & OS-fold 
(mean + SE) in the 12.5 mg/kg tryptophan-treated 
animals, 41 -I 15fold in the 50 mg/kg group and by 
81 + 15-fold in the 100 mg/kg group (fig.2). An ad- 
ditional group of animals received tryptophan at 
250 mg/kg. In these rats, dialysate tryptophan 
levels increased by 17 + 3-fold and QUIN concen- 
trations increased by 230 + 70-fold (not shown). 
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The levels of QUIN peaked at 150 min in the 100 
mg/kg animals and at 30 min in the 12.5 mg/kg 
animals. The rate of increase in QUIN levels over 
the first 30 min however appears identical, sug- 
gesting saturation of the enzyme even at the lowest 
dose of tryptophan and obtainment of maximal en- 
zymatic rate (I’,,). Tryptophan levels peaked be- 
tween 30 and 60 min, 5-HT peaked at 90 min and 
5-HIAA levels had a delayed increase reaching a 
plateau at 150-180 min (fig.1). 
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Fig.1. Rats were anaesthetized and microdialysis probes im- 
planted into left and right striata. 120 min following probe im- 
plantation, 3 consecutive 30-min samples were collected to ob- 
tain a baseline measurement. Rats then received either 0.9010 
saline (n = 5) or tryptophan in a saline solution in doses of 50 
(n = 5) or 100 mg/kg i.p. (n = 5). Dialysates were collected for 
the following three hours, with the right striatal dialysates 
assayed for tryptophan, 5-HT and 5-HIAA. Mean basal levels 
of tryptophan, 5-HIAA and 5-HT did not differ between 
groups, with concentrations of 0.45 f 0.12 pM, 210 f 28 nM 
and 0.73 kO.1 nM, respectively, uncorrected for recovery 
(means f SE). Data represent (a) tryptophan, (b) 5-HT, and (c) 
5-HIAA concentrations as a percentage of baseline values; ver- 
tical bars represent he SE. Tryptophan values in both 50 and 
100 mg/kg treated animals at all time points are significantly 
elevated compared to saline treated controls. 5-HT levels are 
significantly elevated above control values at all time points be- 
tween 60 and 150 min in the animals receiving 100 mg/kg, and 
at 60,90 and 120 min in the 50 mg/kg group. 5-HIAA levels are 
significantly elevated from 90 to 180 min and from 60 to 180 min 
in the 50 and 100 mg/kg groups, respectively. Values significant 
at ~~0.05, Student’s t-test. 
10 
The basal QUIN levels obtained in dialysates 
prior to tryptophan or saline administration were 
45 + 12 nM. The in vitro recovery efficiency of the 
probes at the 0.6 &min perfusion rate was be- 
tween 30 and 40%. Therefore, assuming identical 
diffusion and recovery kinetics in vivo, the basal 
extracellular concentration of QUIN would be ap- 
prox. 120 nM. However, microdialysis is believed 
to underestimate true ECF levels of compounds us- 
ing in vitro recovery and it is likely that actual ECF 
concentrations may be 5- or even IO-times higher 
[451. 
4. DISCUSSION 
These data suggest that changes in brain tryp- 
tophan availability have a marked influence on 
t I I I I I 
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Fig.2. Rats were anaesthetized and microdialysis probes were implanted in left and right striata. 120 min following probe implantation, 
3 consecutive 30-min samples were collected to obtain a baseline measurement. Tryptophan (12.5,50 or 100 mg/kg, all groups (n= 5)). 
or 0.9% saline (n = 5) was then administered i.p. and dialysis continued for a further 180 min. The left striatal dialysates were im- 
mediately frozen and subsequently assayed for QUIN using CC/MS. Basal QUIN levels were similar in all groups, 45 + 9 nM, 
mean i SE, uncorrected for in vitro recovery. Data represent dialysate QUIN concentrations as a percentage of baseline with vertical 
bars representing the SE. Levels of quinolinic acid are significantly elevated above saline-treated control values in the 30 and 60 min sam- 
ple for the 12.5 mg/kg tryptophan treated group; and at 30 min and all time points thereafter in the 50 and 100 mg/kg groups. ~~0.05, 
Student’s t-test, unpaired. 
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levels of QUIN within striatal ECF. In addition, 
this relationship exists even with doses of tryp- 
tophan which may result in alterations in plasma 
levels well within the physiological range. This 
coupling between acute tryptophan loading and 
striatal ECF QUIN is of much greater magnitude 
than the relationship which exists between brain 
tryptophan availability and ECF 5-HT. However, 
the ECF levels of 5-HT obtained by microdialysis 
may not accurately reflect synaptic release, and are 
perhaps more appropriately considered as an in- 
dicator of synaptic spillover, as high-affinity up- 
take of the transmitter may attenuate the changes 
in release as monitored by microdialysis. 
Tryptophan inhibits raphe neuron firing within 
minutes of its administration [46] and although the 
5-HT content within striatal serotoninergic 
neuronal terminals is likely to be increased before 
60 min, the delayed, small increase in ECF levels 
we observed may in part be mediated by partial 
return of raphe neuron firing as seen in slice 
preparations (Sprouse, J. and Aghajanian, G.K., 
personal communication). The small and delayed 
release of 5-HT in vivo following tryptophan ad- 
ministration is also in agreement with previous 
studies using ventricular fluid withdrawal [47], 
ependymal caudate surface fluid collections [48], 
and in vivo voltammetry [49]. 
Levels of QUIN of 1OpM have been shown to be 
toxic in neuronal cell cultures [50] and injection of 
as little as 12 nmol directly into the striatum causes 
neuronal death at the site of infusion [28,5 11. Peak 
estimated ECF levels of QUIN after both the 100 
and 250 mg/kg doses exceed 10 pM; these levels 
may prove to be neurotoxic. The functional signi- 
ficance of the QUIN elevations observed following 
the administration of lower doses of tryptophan is 
unknown. However, as a specific agonist of the N- 
Me-D-Asp receptor, small alterations in ECF 
QUIN levels may modulate N-Me-D-Asp receptor 
number and/or activity and thereby influence ex- 
citatory amino acid neurotransmission. Thus, it 
appears possible that QUIN, a compound pre- 
dominantly synthesized and catabolized by glia 
[52] may act as a neuromodulatory substance, 
although not meeting classical criteria for 
neurotransmitters [53]. 
In Hungtinton’s Disease, the activity of the 
QUIN-synthesizing enzyme, 3-hydroxyanthranilic 
oxygenase is increased by almost 4-fold in the 
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striatum [54], whereas that of the QUIN-degrading 
enzyme, quinolinate phosphoribosyltransferase, is 
relatively unaffected [55]. Combined with evidence 
from our laboratory that QUIN injected into the 
striatum may produce selective neuronal degenera- 
tion similar to the pattern observed in Hun- 
tington’s Disease [30], these data indicate that this 
disease may be caused by a disorder of tryptophan 
metabolism. Indeed, isolated case reports have 
shown rapid clinical deterioration in juvenile Hun- 
tington’s Disease patients following the repeated 
ingestion of pharmacological doses of tryptophan 
[56], and one study has demonstrated correlation 
of free plasma tryptophan levels with the severity 
of chorea [57]. The potential excitatory effects of 
the tryptophan-induced increase in ECF QUIN 
may be antagonized however by concomitant in- 
creases in kynurenic acid (KYNA). KYNA, another 
tryptophan metabolite of the kynurenine pathway, 
acts as a N-Me-D-Asp antagonist [58] and when 
coinjected with QUIN can protect against both the 
neurotoxicity and convulsant activity of QUIN 
[59]. Tissue levels of KYNA have been shown to in- 
crease following tryptophan loading (100 mg/kg 
tryptophan increasing levels less than 2-fold) [60]. 
Although this is a trivial increase compared to that 
of lOO-fold we observed in ECF QUIN, ECF 
KYNA was not measured in the present study (see 
below) and it is possible that levels within this com- 
partment increase much more than tissue levels. 
Elevated ECF concentrations of KYNA might 
therefore protect against he putative QUIN toxici- 
ty under tryptophan loading conditions. 
The sensitivity of current methods for assay of 
KYNA is in the low picomole range [60] (cf. low 
femtomole sensitivity for QUIN) and such methods 
will require major improvement before KYNA will 
be able to be measured in dialysis perfusates. 
In conclusion, QUIN may be added to the list of 
endogenous neuroactive substances whose brain 
levels are influenced by physiological changes in 
plasma precursor concentrations. The functional 
significance of the observed changes in brain ex- 
tracellular levels of QUIN remains to be eluci- 
dated. Because of the well established neuro- 
toxicity of QUIN and the large increases seen in 
ECF QUIN levels after tryptophan administration 
we recommend that the indiscriminate sale and 
casual self-administration of tryptophan from 
health food stores should be curtailed [61], as cer- 
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tain subsets of the population may be particularly 
vulnerable to QUIN-mediated toxic effects. 
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